Patent · US Active

Substituted benzylindazoles for use as BUB1 kinase inhibitors in the treatment of hyperproliferative diseases

US10604532B2 · kind B2 · utility

0Cited by

9References

6Claims

0Family size

Assignees

Bayer Intellectual Property GmbH · DE
Bayer Pharma Aktiengesellschaft · DE

Inventors

Marion Hitchcock · Berlin, DE
Anne Mengel · Berlin, DE
Vera Pütter · Berlin, DE
Gerhard Siemeister · Berlin, DE
Antje Margret Wengner · Berlin, DE
Hans Briem · Bremen, DE
Knut Eis · Berlin, DE
Volker Schulze · Hohen Neuendorf, DE
Amaury Ernesto Fernandez-Montalvan · Leverkusen, DE
Stefan Prechtl · Berlin, DE
Simon Holton · Berlin, DE
Jörg Fanghänel · Berlin, DE
Philip Lienau · Berlin, DE
Cornelia PREUSSE · Berlin, DE
Mark Jean Gnoth · Mettmann, DE

Key dates

Filing date	Mar 21, 2019
Grant date	Mar 31, 2020
Priority date	—
Expiry date	Mar 21, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D413/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compounds of formula (I) which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.